Skip to main content

Generic DDAVP Availability

Last updated on May 11, 2022.

DDAVP is a brand name of desmopressin, approved by the FDA in the following formulation(s):

DDAVP (desmopressin acetate - injectable;injection)

  • Manufacturer: FERRING PHARMS INC
    Approval date: March 30, 1984
    Strength(s): 0.004MG/ML [RLD] [AP]
  • Manufacturer: FERRING PHARMS INC
    Approval date: April 25, 1995
    Strength(s): 0.015MG/ML (discontinued)

DDAVP (desmopressin acetate - solution;nasal)

  • Manufacturer: FERRING PHARMS INC
    Approved Prior to Jan 1, 1982
    Strength(s): 0.01% (discontinued) [RLD]

DDAVP (desmopressin acetate - spray, metered;nasal)

  • Manufacturer: FERRING PHARMS INC
    Approval date: February 6, 1989
    Strength(s): 0.01MG/SPRAY (discontinued) [RLD]

DDAVP (desmopressin acetate - tablet;oral)

  • Manufacturer: FERRING PHARMS INC
    Approval date: September 6, 1995
    Strength(s): 0.1MG [RLD] [AB], 0.2MG [RLD] [AB]

Has a generic version of DDAVP been approved?

Yes. The following products are equivalent to DDAVP:

desmopressin acetate injectable;injection

  • Manufacturer: AM REGENT
    Approval date: February 14, 2019
    Strength(s): 0.004MG/ML [AP]
  • Manufacturer: SAGENT PHARMS INC
    Approval date: August 22, 2017
    Strength(s): 0.004MG/ML [AP], 0.004MG/ML [AP]
  • Manufacturer: SUN PHARM INDS LTD
    Approval date: January 25, 2013
    Strength(s): 0.004MG/ML [AP]
  • Manufacturer: TEVA PHARMS USA
    Approval date: October 15, 1997
    Strength(s): 0.004MG/ML [AP]
  • Manufacturer: UBI
    Approval date: February 14, 2020
    Strength(s): 0.004MG/ML [AP]
  • Manufacturer: UBI
    Approval date: September 17, 2020
    Strength(s): 0.004MG/ML [AP]

desmopressin acetate tablet;oral

  • Manufacturer: ABHAI LLC
    Approval date: January 28, 2019
    Strength(s): 0.1MG [AB], 0.2MG [AB]
  • Manufacturer: ACTAVIS LABS FL INC
    Approval date: July 1, 2005
    Strength(s): 0.1MG [AB], 0.2MG [AB]
  • Manufacturer: APOTEX INC
    Approval date: March 7, 2006
    Strength(s): 0.1MG [AB], 0.2MG [AB]
  • Manufacturer: GLENMARK PHARMS LTD
    Approval date: May 28, 2015
    Strength(s): 0.1MG [AB], 0.2MG [AB]
  • Manufacturer: HERITAGE PHARMA
    Approval date: May 26, 2017
    Strength(s): 0.1MG [AB], 0.2MG [AB]
  • Manufacturer: NOVAST LABS
    Approval date: June 6, 2019
    Strength(s): 0.1MG [AB], 0.2MG [AB]

Note: No generic formulation of the following products are available.

  • desmopressin acetate - solution;nasal
  • desmopressin acetate - spray, metered;nasal

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DDAVP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.